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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Serum autoantibodies have been found in patients with oral lichen pla-
nus (OLP). This study evaluated whether OLP patients had significantly higher frequencies of
serum smooth muscle antibody (SMA) than healthy control individuals, and assessed whether
levamisole treatment could modulate the serum SMA levels in OLP patients.
Methods: This study used an indirect immunofluorescence technique to measure the baseline
serum SMA levels in a group of 647 OLP patients and 53 controls. Ninety-five SMA-positive OLP
patients were treated with levamisole under a regular follow-up schedule, and their serum SMA
levels were measured after treatment.
Results: The frequencies of serum SMA in patients with OLP (21.9%), erosive OLP (EOLP,
21.6%), major EOLP (17.9%), minor EOLP (24.2%), and nonerosive OLP (24.4%) were all signifi-
cantly higher than that (0%) in healthy controls (all p < 0.001). Of 142 SMA-positive OLP pa-
tients, 95 were treated with levamisole under a regular follow-up schedule. Treatment with
levamisole for a period of 2e29 months (mean, 9.4  6.0 months) effectively reduced the high
mean serum SMA titer (71.0  7.2) at baseline to an undetectable level (0) in all SMA-positive
OLP patients, regardless of different initial serum SMA titers.of Dentistry, National Taiwan University Hospital, 1, Chang-Te Street, Taipei 10048, Taiwan.
oo.com.tw (A. Sun).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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Smooth muscle antibody in oral lichen planus 353Conclusion: There was a significantly higher frequency of serum SMA (21.9%) in OLP patients
than in healthy controls. Treatment with levamisole for 2e29 months significantly reduced
the high serum SMA to an undetectable level, and significantly improved the signs and symp-
toms in all treated OLP patients.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Oral lichen planus (OLP) is a chronic inflammatory oral
mucosal disease commonly found in the dental clinic. Pre-
vious study showed involvement of both antigen-specific
and nonspecific mechanisms in OLP. Antigen-specific
mechanisms include antigen presentation by basal kerati-
nocytes and antigen-specific keratinocyte killing by CD8þ
cytotoxic T lymphocytes. Nonspecific mechanisms comprise
mast cell degranulation and matrix metalloproteinase
activation in OLP lesions.1 Through mast cell/T cell in-
teractions in OLP lesions, mast-cell-released cytokines,
chemokines and matrix metalloproteinases can promote
T cell activation, migration, proliferation, and differentia-
tion.2 Histologically, OLP is characterized by hyperkeratotic
and acanthotic epithelium with liquefaction degeneration
of basal epithelial cells, and a marked band-like sub-
epithelial infiltrate of mononuclear cells that are predom-
inantly CD8þ. CD4þ cells are observed predominantly in
the deep lamina propria.3 An increase in histocompatibility
leukocyte antigen (HLA)-D-related (DR)-positive CD3þ cells
in both the local lesional tissues and peripheral lympho-
cytes also indicates T cell activation in OLP.4,5 The above
findings suggest that OLP is a T cell-mediated inflammatory
disease.
Levamisole is an immunomodulator that can modulate
T cell-mediated immunity.6e11 Our previous studies have
found that levamisole can also modulate abnormal serum
interleukin (IL)-6, IL-8, tumor necrosis factor-a, antibasal
cell antibody (anti-BCA), antinuclear antibody (ANA),
antithyroglobulin antibody (TGA), and antithyroid micro-
somal antibody (TMA) levels to normal in patients with OLP
or erosive OLP (EOLP).6e11 The presence of serum auto-
antibodies including anti-epithelial cell antibody, ANA,
smooth muscle antibody (SMA), antimitochondrial anti-
body, gastric parietal cell antibody (GPCA), TGA, TMA, and
antidesmoglein 1 and antidesmoglein 3 antibodies has
been shown in several different groups of OLP
patients.9e17
Our previous studies found that the serum SMA-
positive rates are 20%, 17%, 41%, and 23.9% in patients
with OLP, recurrent aphthous ulcerations (RAU), oral
squamous cell carcinoma (OSCC), and oral submucous
fibrosis (OSF), respectively.18,19 In this study, we exam-
ined the frequencies of serum SMA in a group of 647
Taiwanese OLP patients and in 53 healthy control in-
dividuals. We tried to assess whether there was a signif-
icantly higher frequency of serum SMA in Taiwanese OLP
patients than in healthy controls, and whether levamisole
treatment could modulate serum SMA levels in OLP
patients.Materials and methods
Patients and controls
The study group consisted of 647 OLP patients (111 men and
536 women; age range, 21e88 years; mean age, 55.4 years)
without lichen planus of other mucosal or skin surfaces. The
normal control group consisted of 53 healthy controls
(8 men and 45 women; age range, 21e83 years; mean age,
54.7 years) without any oral mucosal or systemic diseases.
All the patients and controls were seen consecutively,
diagnosed, and treated in the Department of Oral Diagnosis
of National Taiwan University Hospital from July 2004 to
February 2012. OLP patients with areca quid chewing habit,
hypertension, and autoimmune diseases such as systemic
lupus erythematosus, rheumatoid arthritis, Sjo¨gren’s syn-
drome, pemphigus vulgaris, and cicatricial pemphigoid
were excluded. In addition, none of them had taken any
prescription medication for at least 3 months prior to
entering the study. The 647 OLP patients included 561 with
EOLP (98 men and 463 women; age range, 21e88 years;
mean age, 55.7 years) and 86 with nonerosive OLP (NEOLP;
13 men and 73 women; age range, 24e83 years; mean age,
53.2 years). They were selected according to the following
criteria: (1) a typical clinical presentation of radiating
grayish white Wickham striae, papules and plaques, sepa-
rately or in combination (NEOLP), or erosion or ulceration
of the oral mucosa (EOLP); and (2) biopsy specimens char-
acteristic of OLP, that is, hyperkeratosis or parakeratosis, a
slightly acanthotic epithelium with liquefaction degenera-
tion of the basal epithelial cells, a prominent band-like
lymphocytic infiltrate in the lamina propria, and the
absence of epithelial dysplasia. EOLP was further divided
into major and minor types according to previously
described criteria.6e8
All OLP patients, regardless of their subtype, were
treated with levamisole that was administered at a dose of
50 mg twice daily for patients with 30e50 kg body weight,
or 50 mg three times daily for patients with 50e70 kg body
weight, for 3 consecutive days at the beginning of each 2-
week interval. Compliance was monitored by asking the
patients to record the time at which each drug was taken.
Prior to the start of therapy, clinical data on all cases were
recorded according to a set protocol, and the patients were
examined by the same dentist during each visit. Patients
were monitored once monthly to record clinical responses
after treatment.
Blood samples were taken from OLP patients prior to
treatment and from normal controls to measure the serum
SMA, ANA, and hepatitis C virus antibody (HCVA) levels. The
ANA and HCVA levels were concurrently determined to
Table 1 Frequencies of serum smooth muscle antibody
(SMA) in different groups of oral lichen planus (OLP) pa-





OLP (n Z 647) 142 21.9 <0.001
Age 50 y (n Z 199) 40 20.1 <0.001
Age >50 y (n Z 448) 102 22.8 <0.001
Men (n Z 111) 21 18.9 <0.001
Women (n Z 536) 121 22.6 <0.001
EOLP (n Z 561) 121 21.6 <0.001
Major (n Z 234) 42 17.9 <0.001
Minor (n Z 327) 79 24.2 <0.001
NEOLP (n Z 86) 21 24.4 <0.001
Healthy controls (n Z 53) 0 0
EOLP Z erosive OLP; NEOLP Z nonerosive OLP.
* Comparison between healthy control group and any other
groups by Chi-square test.
354 K.-M. Wu et al.evaluate whether there was an association of serum SMA
positivity with the serum ANA or HCVA positivity. To assess
whether the serum SMA levels in OLP patients were reduced
after treatment with levamisole, blood samples were ob-
tained serially every 2e3 months until the serum SMA levels
became undetectable. Informed consent was obtained from
each patient or control prior to blood sample collection. This
studywas reviewed and approved by the Institutional Review
Board at the National Taiwan University Hospital.
Determination of serum SMA and ANA levels
The circulating SMA and ANA were detected by the indirect
immunofluorescence technique with HEp-2 cells (for ANA;
Medical & Biological Laboratories Co., Nagoya, Japan) and
rat kidney (for SMA) as substrates as described previ-
ously.15,19 In brief, HEp-2 cells or 5 mm-thick cryostat sec-
tions of substrate tissues on slides were reacted with
serially diluted OLP patients’ and controls’ sera in a moist
chamber at room temperature for 30 minutes. The initial
dilution of the sera was 1:20 with PBS. After washing, the
sections were incubated with fluorescein isothiocyanate-
labeled goat antihuman IgG antiserum (Boehringer Man-
nheim Biochemicals, Indianapolis, IN, USA), which was
prediluted and supplied in a dropper vial by the manufac-
turer and was ready-to-use in 30 minutes. The sections
were washed again, mounted with buffered glycerine, and
examined with a fluorescence microscope (Olympus Optical
Company Ltd., Tokyo, Japan). Sera were scored as positive
when they produced fluorescence at a dilution of 160 or
more for ANA, and of 20 or more for SMA.
Determination of HCVA level
The serum HCVA was detected by an ARCHITECT anti-HCV
assay (Abbott Laboratories, Abbott Park, IL, USA), as
described previously.20,21 This assay was an automated
chemiluminescent microparticle immunoassay based on the
enzyme immunoassay principle. In contrast to the enzyme
immunoassay, where the antigeneantibody complexes
were detected by enzyme-labeled conjugate, the chemi-
luminescent microparticle immunoassay used acridinium-
labeled conjugate as the detection system. The resulting
chemiluminescent reaction was measured as relative light
units (RLUs). ARCHITECT Anti-HCV was designed to detect
antibodies to structural and nonstructural proteins of the
HCV genome (NS3, NS4, core). The ARCHITECT Anti-HCV
assay cutoff value was calculated by the following for-
mula: calibrator 1 mean RLU value 0.074 Z cutoff RLU.
ARCHITECT Anti-HCV assay delivered specimen results as a
ratio of the specimen signal (in RLU) to the cutoff value (S/
CO). S/CO ratios of 1.00 were considered reactive for
HCVA; ratios <1.00 were nonreactive for HCVA.
Statistical analysis
The difference in frequency of serum SMA was compared
between any two groups by the Chi-square test. The serum
levels of SMA at baseline and after treatment were
compared to each other using a paired t test. The result
was considered to be significant if p < 0.05.Results
There were 142 OLP patients (21.9%) with a serum SMA titer
20. The frequencies of serum SMA in different groups of
OLP patients and 53 healthy controls are shown in Table 1.
The frequencies of serum SMA in patients with OLP (21.9%),
EOLP (21.6%), major EOLP (17.9%), minor EOLP (24.2%), and
NEOLP (24.4%) were all significantly higher than that (0%) in
healthy controls (all p < 0.001). In addition, OLP patients
aged 50 years or >50 years and male or female OLP pa-
tients also had a significant higher frequency of serum SMA
than healthy controls (all p < 0.001; Table 1). The serum
SMA positive rate was not associated with OLP patients’ age
and gender, type of OLP, type of EOLP, serum ANA-
positivity, and serum HCVA-positivity (all p > 0.05;
Table 2). Of 142 SMA-positive OLP patients, 95 were treated
with levamisole under a regular follow-up schedule in our
dental clinic. Treatment with levamisole for a period of
2e29 months (mean, 9.4  6.0 months) effectively reduced
the high mean serum SMA level (71.0  7.2) at baseline to
an undetectable level (0) in all 95 SMA-positive OLP pa-
tients, including those with EOLP, major or minor EOLP, and
NEOLP (Table 3). Furthermore, when OLP patients were
divided into five different groups according to different
initial serum SMA titers ranging from 1:20 to 1:320, all the
serum SMA levels at baseline were effectively reduced to an
undetectable level (0, all p  0.002) after treatment with
levamisole for 2e29 months (Table 3). The 95 SMA-positive
OLP patients also had significant improvement in signs and
symptoms of OLP after levamisole treatment for 2e29
months (such as a reduction in lesion size and pain caused
by the lesion, healing of erosive or ulcerative lesions, and
transformation of EOLP into NEOLP).
Discussion
This study showed that the serum SMA-positive rate was
21.9% for 647 OLP patients, 21.6% for 561 EOLP patients,
Table 2 Comparison of serum smooth muscle antibody








50 (n Z 199) 40 159 0.513
>50 (n Z 448) 102 346
Patients’ gender
Men (n Z 111) 21 90 0.471
Women (n Z 536) 121 415
Type of OLP
EOLP (n Z 561) 121 440 0.649
NEOLP (n Z 86) 21 65
Type of EOLP (n Z 561)
Major (n Z 234) 42 192 0.097
Minor (n Z 327) 79 248
ANA
Positive (n Z 136) 32 104 0.700
Negative (n Z 511) 110 401
HCVA
Positive (n Z 76) 19 57 0.591
Negative (n Z 571) 123 448
ANA Z antinuclear antibody; EOLP Z erosive OLP;
HCVA Z hepatitis C virus antibody; NEOLP Z nonerosive OLP.
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demonstrated the presence of serum SMA in 8.4% of 320 OLP
patients, 8.2% of 292 EOLP patients, and 10.7% of 28 NEOLP
patients.17 We suggest that the differences in the serum
SMA-positive rate between these two groups of OLP pa-
tients was due to different sample sizes in these two
studies. Although the serum SMA-positive rates were
different, NEOLP patients tended to have a slightly higher
serum SMA-positive rate than EOLP patients in these two
studies. In the present study, we treated the OLP patientsTable 3 Serum titers of smooth muscle antibody (SMA) prior to
(OLP) patients, including 33 with major and 48 with minor erosiv
Treatment
modality
OLP type or SMA titer Duration of trea
(mo)
Range Mea
Levamisole OLP (n Z 95) 2e29 9.4
Levamisole EOLP (n Z 81) 2e29 9.3
Levamisole Major (n Z 33) 2e29 9.8
Levamisole Minor (n Z 48) 2e21 9.0
Levamisole NEOLP (n Z 14) 3e25 10.0
Levamisole SMA titer Z 20 (n Z 37) 2e16 6.6
Levamisole SMA titer Z 40 (n Z 16) 2e21 9.6
Levamisole SMA titer Z 80 (n Z 25) 2e29 11.6
Levamisole SMA titer Z 160 (n Z 13) 3e25 12.0
Levamisole SMA titer Z 320 (n Z 4) 9e18 12.8
SD Z standard deviation; SEM Z standard error of the mean.
* Comparison of serum SMA titers between patients at baseline andwith levamisole and found that all different initial serum
SMA titers in different groups of OLP patients could be
reduced to an undetectable level after treatment for 2e29
months, although OLP patients with lower SMA titers
needed shorter treatment periods to render the SMA titers
to an undetectable level. Our previous studies have also
shown the disappearance of serum anti-BCA in all three of
six anti-BCA-positive EOLP patients, the disappearance of
serum ANA in three ANA-positive EOLP patients, partial
reduction or absence of serum TGA in 36 of 41 TGA-positive
OLP patients and of serum TMA in 46 of 48 TMA-positive OLP
patients, and complete regression of serum ANA in all 79
OLP patients after levamisole treatment for different
periods.9e11 In addition, treatment with levamisole for
0.5e7.5 months can significantly reduce the abnormally
high serum IL-6, IL-8, and tumor necrosis factor-a levels to
normal in patients with OLP or EOLP.7,8 The most important
fact is that the reduction of autoantibody or cytokine levels
after levamisole treatment is always accompanied by sig-
nificant improvement of signs and symptoms in OLP
patients.6e11 These findings suggest that levamisole treat-
ment decreases the abnormal serum autoantibody and
cytokine levels to normal in OLP patients, and is an effec-
tive treatment modality for OLP.
Previous studies have demonstrated an overall incidence
of 21e82% for serum autoantibodies in several different
groups of OLP or EOLP patients.10e17 The frequencies of
serum TGA and TMA are 21.6% and 24.5% in 278 OLP pa-
tients, respectively.10 The positive rate of serum ANA is
23.2% in 583 OLP patients.11 Serum anti-BCA is discovered in
34 (54%) of 63 OLP patients.12 Serum autoantibodies
including rheumatoid factor, ANA and SMA are found in 27%
of 30 OLP patients and in 9% of 23 controls.13 The presence
of circulating antibodies to epithelial antigen was shown in
57% of 14 HCVA-positive OLP patients and in none of 14
HCVA-negative patients.14 Carrozzo et al15 demonstrated
the presence of serum autoantibodies, including ANA, SMA,
antimitochondrial antibody, GPCA, and antithyroid anti-
body in 41% of 27 HCVA-positive OLP patients and in 52% ofor after treatment with levamisole in 95 oral lichen planus
e OLP (EOLP), and 14 with nonerosive OLP (NEOLP).
tment Serum titers of SMA (fold of
dilution of serum)
p*
n  SD At baseline After treatment
Mean  SEM Mean  SEM
 6.0 71.0  7.2 0 <0.001
 5.9 67.4  7.4 0 <0.001
 6.8 80.0  11.3 0 <0.001
 5.3 58.8  9.7 0 <0.001
 6.3 91.4  24.0 0 0.002
 3.7 20 0 <0.001
 4.7 40 0 <0.001
 7.4 80 0 <0.001
 7.1 160 0 <0.001
 4.5 320 0 <0.001
after levamisole treatment by paired t test.
356 K.-M. Wu et al.23 HCVA-negative patients. Lukac et al16 showed, by
enzyme linked immunosorbent assay, significantly higher
concentrations of circulating autoantibodies to desmoglein
1 and desmoglein 3 in 32 EOLP patients compared with 50
healthy controls. Indirect immunofluorescence also
revealed significantly higher frequencies of desmoglein
autoantibodies in EOLP patients (82%, 18/22) than in
healthy controls (5%, 1/20).16 Our previous study demon-
strated an overall incidence of 60.9% for the presence of
serum autoantibodies in a large group of 320 OLP patients,
and significantly higher frequencies of serum ANA, GPCA,
TGA, and TMA in OLP patients than in healthy controls.17
The above findings demonstrate significantly higher fre-
quencies of serum autoantibodies in OLP patients than in
healthy controls and also indicate that OLP carries a high
potential toward an autoimmune disease.
The present study showed a significantly higher serum
SMA positive rate in NEOLP, major EOLP, and minor EOLP
patients. Our previous studies found the presence of
serum SMA in 20%, 17%, 41%, and 23.9% of patients with
OLP, RAU, OSCC, and OSF, respectively.18,19 Myofibroblasts
identified by a-smooth muscle actin antibody are detec-
ted in OSCC and OSF lesions22e24 as well as in wound
healing and fibrocontractive diseases such as liver
cirrhosis and renal fibrosis.25 EOLP and RAU are oral
mucosal diseases characterized by multiple recurrences of
oral ulcers followed by wound healing. Repeated
destruction of oral mucosal tissues by the disease process
of OLP, RAU, OSCC, and OSF may cause the release of
smooth muscle antigens from myofibroblasts and blood
vessel wall into the local tissues and blood circulation.
These smooth muscle antigens are phagocytosed and
processed by macrophages and B cells, and in turn, pre-
sented to helper/inducer T cells in the oral mucosal le-
sions, regional lymph nodes, and blood circulation of OLP,
RAU, OSCC, and OSF patients. With the help of T cells,
antigen-specific activated B cells thus produced high
levels of SMA in the local oral mucosal lesions and blood
circulation of OLP, RAU, OSCC, and OSF patients. In
addition, our recent study showed that 26.3%, 21.3%,
24.4%, and 12.8% of 320 OLP patients are GPCA-, TGA-,
TMA-, and HCVA-positive, respectively.17 This study also
demonstrated an HCVA-positive rate of 11.7% in 647 OLP
patients. GPCA-positive, TGA/TMA-positive, and HCVA-
positive OLP patients may also have underlying autoim-
mune atrophic gastritis, autoimmune thyroid disease, and
chronic liver disease, respectively.26e29 Therefore, these
patients may have more smooth muscle antigens released
in the local gastric, thyroid and liver tissues and blood
circulation. By similar mechanisms, these released smooth
muscle antigens may stimulate the antigen-specific acti-
vated B cells to produce more SMA. The locally-produced
SMA in the interstitial fluid may diffuse into blood capil-
laries or be drained into the lymphatic vessels, and finally
reach the blood circulation. The locally-secreted SMA,
together with those produced in the blood circulation
eventually give rise to significantly higher levels of serum
SMA in OLP patients than in healthy controls. The disap-
pearance of the serum SMA after levamisole treatment-
induced healing of the OLP lesions in the present study
also suggests that the principal smooth muscle auto-
antigens may come from the local OLP lesions.It has been well established that chronic HCV infection
plays important roles in the production of noneorgan-spe-
cific autoantibodies, including SMA. Serum SMA is detected
33e37% of HCV-infected patients.29 An SMA-positive rate of
25% is found in 175 Indian patients with chronic liver dis-
ease.30 In addition, polyclonal B cell activation by persis-
tent HCV infection has been proposed as another
mechanism for the production of autoantibodies.31 The
findings from these three studies also indicate the contri-
bution of chronic HCV infection or liver disease to the
production of SMA.
This study showed a significantly higher frequency of
serum SMA (21.9%) in OLP patients than in healthy controls.
Treatment with levamisole for 2e29 months could signifi-
cantly reduce the high serum SMA concentrations to unde-
tectable levels, and significantly improve signs and
symptoms of OLP patients. Therefore, we conclude that
levamisole treatment can modulate the high serum SMA
titer to undetectable levels in OLP patients, and is an
effective treatment modality for OLP.
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